Oral Iron Therapy for IBD Patients with Iron Deficiency Anemia Now Available in UK

Oral Iron Therapy for IBD Patients with Iron Deficiency Anemia Now Available in UK
Shield Therapeutics  announced that Feraccru (ferric maltol), its oral treatment for inflammatory bowel disease (IBD) patients with iron deficiency anemia (IDA), is now available in the U.K. "There is a real unmet need for a well-tolerated oral iron replacement for IBD patients with IDA who have failed oral ferrous products," Dr. Tariq Iqbal, consultant gastroenterologist at Queen Elizabeth Hospital in Birmingham, U.K. said in a press release. "Oral ferrous treatments aren't well tolerated and patients often don't adhere to treatment; this limits their efficacy. The availability of Feraccru is an important step in helping to fulfill this unmet need and may help reduce the need to progress to IV [intravenous] iron treatments." Dr. Iqbal noted that iron therapy given intravenously "works well in IBD," but its use is complicated by many patients also being on other intravenous medications, like infused biologic therapy. "Feraccru provides another potential option for treating these patients quickly and efficiently," he said. Feraccru was tested in a Phase 3 clinical trial program in 128 adults with IDA secondary to IBD, who did not respond to other oral iron products. The 12- and 64-week trials, called AEGIS, showed that Feraccru was both effective and well-tolerated. After 12 weeks of treatments with oral Feraccru (30 mg twice daily), patients showed significant improvement in their hemoglobin levels compared to those given a placebo, and improvement continued through the trial's safety ph
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *